Bumetanide (BT)
Bumex; Burinex
Bumetanide is a loop diuretic of the sulfamyl category to treat heart failure. It is often used in people in whom high doses of furosemide are ineffective. It is marketed by Hoffmann-La Roche. The main difference between the two substances is in bioavailability and pharmacodynamic potency. It is said to be a more predictable diuretic, meaning that the predictable absorption is reflected in a more predictable effect. In the brain, bumetanide blocks the NKCC1 cation-chloride co-transporter, and thus decreases internal chloride concentration in neurons. In turn, this concentration change makes the action of GABA more hyperpolarizing, which may be useful for treatment of neonatal seizures, that quite often are not responsive to traditional GABA-targeted treatment, such as barbiturates. Bumetanide is therefore currently under evaluation as a prospective antiepileptic drug.
Organism species: Pan-species (General)
- Customized Service n/a Complete Antigen of Bumetanide (BT) Antigenic Transformation Customized Service Offer
- Customized Service n/a Monoclonal Antibody to Bumetanide (BT) Monoclonal Antibody Customized Service Offer
- Customized Service n/a Polyclonal Antibody to Bumetanide (BT) Polyclonal Antibody Customized Service Offer
- Customized Service n/a CLIA Kit for Bumetanide (BT) CLIA Kit Customized Service Offer
- Customized Service n/a ELISA Kit for Bumetanide (BT) ELISA Kit Customized Service Offer
